DURECT, based in Cupertino, California, develops investigational therapies, including Larsucosterol for alcohol-associated hepatitis. Its FDA-approved products include POSIMIR and PERSERIS, while employing 48 staff since its 2000 IPO.
R Scott Asen bought 87,608 shares of DRRX on 20 August at $1.89 per share, worth a total of $165K. They now own 970,000 DRRX shares, or a 10% holding increase.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
